Odyssey Therapeutics has set terms for a $225 million initial public offering, pricing expected by Friday. The Boston-based biotech is offering 11.25 million shares at $18-20 per share, valuing the company at approximately $1.1 billion post-money at midpoint. Underwriters include Morgan Stanley and Goldman Sachs, with a 30-day greenshoe for an additional 1.69 million shares.
The company develops therapeutics for autoimmune and inflammatory diseases, with three programs in clinical stages. Lead candidate ODY101, a monoclonal antibody targeting IL-15, completed Phase 1b dosing in celiac disease patients in November. The company reported zero dose-limiting toxicities across 48 patients and expects Phase 2 initiation in Q2 2025. Second asset ODY201 entered Phase 1 for ulcerative colitis in September, with interim data expected mid-year. The third program, ODY301 for psoriasis, began first-in-human trials in December with readouts planned for late 2025. Odyssey burned $127 million in the twelve months ending September 2024, holding $318 million in cash before this raise.
This marks the first U.S. biotech IPO exceeding $200 million since April 2023, when Acelyrin priced a $247 million offering at $17 per share and currently trades at $3.12. The eighteen-month window closure followed SVB collapse aftershocks and three consecutive quarters of biotech index declines exceeding 22%. Odyssey's willingness to price now signals either desperation for runway or conviction that allocators have rotated back after the sector's 31% rally from October lows. The IL-15 mechanism distinguishes ODY101 from the crowded IL-23 inhibitor space where five approved therapies compete, but Odyssey lacks partnerships or significant preclinical backup, concentrating risk in three early-stage shots.
Allocators should watch three events: first, whether the deal prices within range or requires a cut, indicating true demand versus underwriter optimism. Second, ODY101 Phase 2 design details expected in April will reveal statistical powering and endpoint choices that determine commercial viability. Third, any partnership announcements before the 180-day lockup expires in July would validate platform value and derisk single-asset dependence. The company's current cash position plus proceeds provides runway into Q3 2026, assuming burn rate holds, leaving six quarters to demonstrate clinical proof-of-concept before needing secondary capital.
If Odyssey closes Friday above $20, Renaissance Capital's biotech IPO index adds a seventh 2025 constituent, already outpacing full-year 2024's five healthcare offerings by Q1.